(R)-(+)-Etomoxir Na | Carnitine palmitoyltransferase inhibitor
NMR (Conforms)
Available Options
| Size: | Price | Quantity | |
|---|---|---|---|
| 5 mg | $60.00 | ||
| 25 mg | $180.00 |
Etomoxir Na (828934-41-4) is an irreversible inhibitor of mitochondrial carnitine palmitoyl transferase 1 (CPT1).1 It is widely used to study fatty acid oxidation. Etomoxir has been investigated as a therapeutic agent for heart disease2, diabetes3, and cancer4,5. Use of etomoxir in concentrations greater than 5 µM induces acute production of ROS with associated evidence of severe oxidative stress in proliferating T cells indicating a loss of specificity for CTP1 at these concentrations.6 200 µM etomoxir inhibited complex I of the electron transport chain.7
References/Citations:
1) Agius et al. (1991), Stereospecificity of the inhibition of etomoxir of fatty acid and cholesterol synthesis in isolated rat hepatocytes; Biochem. Pharmacol. 42 1717
2) Lionetti et al. (2011), Modulating fatty acid oxidation in heart failure; Cardiovasc. Res, 90 202
3) Huebinger et al. (1997), Effects of the carnitine-acyltransferase inhibitor etomoxir on insulin sensitivity, energy expenditure, and substrate oxidation in NIDDM; Horm. Metab. Res. 29 436
4) Pike et al. (2011), Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells; Biochim. Biophys. Acta 1807 726
5) Samudio et al. (2010), Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction; J. Clin. Invest. 120 142
6) O’Connor et al. (2018), The CPT1a inhibitor, etomoxir, induces severe oxidative stress at commonly used concentrations; Sci. Rep. 8 6289
7) Yao et al. (2018), Identifying off-target effects of etomoxir reveals that carnitine palmitoyltransferase I is essential for cancer cell proliferation independent of β-oxidation; PLoS Biol. 16 e2003782
NMR (Conforms)
Safety Data Sheet:
Product Data Sheet:
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Etomoxir Na (828934-41-4) is an irreversible inhibitor of mitochondrial carnitine palmitoyl transferase 1 (CPT1).1 It is widely used to study fatty acid oxidation. Etomoxir has been investigated as a therapeutic agent for heart disease2, diabetes3, and cancer4,5. Use of etomoxir in concentrations greater than 5 µM induces acute production of ROS with associated evidence of severe oxidative stress in proliferating T cells indicating a loss of specificity for CTP1 at these concentrations.6 200 µM etomoxir inhibited complex I of the electron transport chain.7
References/Citations:
1) Agius et al. (1991), Stereospecificity of the inhibition of etomoxir of fatty acid and cholesterol synthesis in isolated rat hepatocytes; Biochem. Pharmacol. 42 1717
2) Lionetti et al. (2011), Modulating fatty acid oxidation in heart failure; Cardiovasc. Res, 90 202
3) Huebinger et al. (1997), Effects of the carnitine-acyltransferase inhibitor etomoxir on insulin sensitivity, energy expenditure, and substrate oxidation in NIDDM; Horm. Metab. Res. 29 436
4) Pike et al. (2011), Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells; Biochim. Biophys. Acta 1807 726
5) Samudio et al. (2010), Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction; J. Clin. Invest. 120 142
6) O’Connor et al. (2018), The CPT1a inhibitor, etomoxir, induces severe oxidative stress at commonly used concentrations; Sci. Rep. 8 6289
7) Yao et al. (2018), Identifying off-target effects of etomoxir reveals that carnitine palmitoyltransferase I is essential for cancer cell proliferation independent of β-oxidation; PLoS Biol. 16 e2003782
Related products
-
ZM-336372 | c-Raf inhibitor
From $60.00CAS:208260-29-1Catalog Number:10-1030Activity:c-Raf inhibitorChemical Name:3-(Dimethylamino)-N-[3-[(4-hydroxybenzoyl)-amino]-4-methylphenyl]benzamideMolecular Weight:389.46Molecular Formula:C23H23N3O3Solubility:Soluble in DMSO (up to 50 mg/ml).Physical Properties:Off-white solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 2 years from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 1 month.Shipping Code:RT -
Ko-143 | BCRP inhibitor
From $110.00CAS:461054-93-3Catalog Number:10-1074Activity:BCRP inhibitorChemical Name:(3S,6S,12aS)-1,2,3,4,6,7,12,12a-Octahydro-9-methoxy-6-(2-methylpropyl)-1,4-dioxopyrazino[1′,2′:1,6]pyrido [3,4-b]indole-3-propanoic acid 1,1-dimethylethyl esterMolecular Weight:469.59Molecular Formula:C26H35N3O5Solubility:Soluble in DMSO (up to 25 mg/ml) or in Ethanol (up to 50 mg/ml).Physical Properties:White solidPurity:98% by TLC
NMR (Conforms)Storage Temperature:-20°CStability:Stable for 2 years from date of purchase as supplied. Protect from exposure to moisture. Solutions in DMSO or ethanol may be stored at -20°C for up to 3 months.Shipping Code:RT -
MK-571 | Cys LT1 antagonist
From $60.00CAS:115104-28-4Catalog Number:10-1039Activity:Cys LT1 antagonistAlternate Names:L-660711Chemical Name:5-(3-(2-(7-Chloroquinolin-2-yl)ethenyl)phenyl)-8-dimethylcarbamyl-4,6-dithiaoctanoic acidMolecular Weight:515.09Molecular Formula:C26H27ClN2O3S2Solubility:Soluble in DMSO (up to 50 mg/ml).Physical Properties:Yellow solidPurity:95% by TLC
NMR (Conforms)Storage Temperature:RTStability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months.Shipping Code:RT
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
20% OFF
For Postdoc
Customers!
Focus Biomolecules • Plymouth Meeting, PA USA • 1-855-FOCUS21
Focus Biomolecules
Plymouth Meeting, PA USA
1-855-FOCUS21
Website Created by Advanta Advertising LLC.